We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...

Individuals with ulcerative colitis have an increased risk for certain types of cancer based on age, instead of treatment type.

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

3 Results A total of six patients, five of which were male, were initiated on ustekinumab between November 2019 and June 2022 at a median age of 15.5 years (range 11–17). The median fecal calprotectin ...

The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

Compared with adalimumab, several biologic medications had superior safety profiles for the treatment of moderate to severe psoriasis.

“The positive results from this confirmatory patient study represent an important step in the development of the Xolair® biosimilar candidate. We look forward to working with our partners to increase ...

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

Updated guidance from the ACG on the management of Crohn’s disease reflects the surge in development of therapeutic options ...

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing USYMRO® to the reference product ...